MedTrace Logo

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

NCT05411744 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-21

No results posted yet for this study

Summary

This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.

Conditions

  • Latent Tuberculosis
  • End Stage Renal Disease
  • Renal Transplant Candidate for Right Kidney
  • Renal Transplant Candidate for Left Kidney

Interventions

DRUG

1 month Rifapentine, Isoniazid and Vitamin B6

Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.

Sponsors & Collaborators

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Pinki Bhatt, MD · Rutgers

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-01-16
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05411744 on ClinicalTrials.gov